JPWO2022035271A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022035271A5
JPWO2022035271A5 JP2023507508A JP2023507508A JPWO2022035271A5 JP WO2022035271 A5 JPWO2022035271 A5 JP WO2022035271A5 JP 2023507508 A JP2023507508 A JP 2023507508A JP 2023507508 A JP2023507508 A JP 2023507508A JP WO2022035271 A5 JPWO2022035271 A5 JP WO2022035271A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
fatty liver
alcoholic fatty
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537895A (ja
JP2023537895A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2021/010780 external-priority patent/WO2022035271A1/ko
Publication of JP2023537895A publication Critical patent/JP2023537895A/ja
Publication of JP2023537895A5 publication Critical patent/JP2023537895A5/ja
Publication of JPWO2022035271A5 publication Critical patent/JPWO2022035271A5/ja
Pending legal-status Critical Current

Links

JP2023507508A 2020-08-14 2021-08-13 三重活性体持続型結合体を有効成分として含む薬学組成物 Pending JP2023537895A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2020-0102604 2020-08-14
KR20200102604 2020-08-14
PCT/KR2021/010780 WO2022035271A1 (ko) 2020-08-14 2021-08-13 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물

Publications (3)

Publication Number Publication Date
JP2023537895A JP2023537895A (ja) 2023-09-06
JP2023537895A5 JP2023537895A5 (https=) 2024-08-20
JPWO2022035271A5 true JPWO2022035271A5 (https=) 2024-08-20

Family

ID=80247218

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507508A Pending JP2023537895A (ja) 2020-08-14 2021-08-13 三重活性体持続型結合体を有効成分として含む薬学組成物

Country Status (11)

Country Link
US (1) US20230302148A1 (https=)
EP (1) EP4197560A4 (https=)
JP (1) JP2023537895A (https=)
KR (1) KR20220021890A (https=)
AU (1) AU2021324792A1 (https=)
CA (1) CA3187742A1 (https=)
IL (1) IL299800A (https=)
MX (1) MX2023001599A (https=)
TW (1) TW202220700A (https=)
WO (1) WO2022035271A1 (https=)
ZA (1) ZA202301081B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4197550A4 (en) * 2020-08-14 2025-10-08 Hanmi Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
SG191252A1 (en) * 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CA2877358A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
WO2017116204A1 (ko) * 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
EP4197550A4 (en) * 2020-08-14 2025-10-08 Hanmi Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION WITH HYPOTENSIVE EFFECT COMPRISING A TRIPLE ACTIVATOR WITH ACTIVITY FOR ALL GLUCAGON, GLP-1, AND GIP RECEPTORS

Similar Documents

Publication Publication Date Title
CN114901683B (zh) 胰岛素衍生物
US20200046725A1 (en) Prodrug Comprising a Drug Linker Conjugate
TWI784914B (zh) 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物
JP4778519B2 (ja) インクレチンホルモン活性を持つペプチドの経上皮送達
JP6076902B2 (ja) 新規な持続型グルカゴン結合体およびこれを含む肥満の予防および治療用薬学的組成物
JP6749845B2 (ja) インスリン及びｇｌｐ−１／グルカゴン二重アゴニストを含む糖尿病治療用組成物
US7291594B2 (en) GLP-1 derivative and preparation thereof absorbable via mucous membrane
KR20240099142A (ko) 병용 요법
WO2016066818A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
CN111132690A (zh) 胰高血糖素和glp-1受体的长效共激动剂
CN105263957A (zh) 治疗肽
MX2014012625A (es) Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
CA2525168A1 (en) Compositions for delivering peptide yy and pyy agonists
JP4824663B2 (ja) 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法
JPWO2022020105A5 (https=)
JP2025000663A (ja) ヒトアミリンアナログペプチド及び使用方法
CN115003320A (zh) 甲状旁腺功能减退的治疗
UA114192C2 (uk) Спосіб одержання фізіологічно активного поліпептидного комплексу
IL291681B2 (en) Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
JP2024178193A (ja) インスリン及びグルカゴンを含む薬学組成物
JP2019514908A5 (https=)
JPWO2022035271A5 (https=)
JPWO2022068920A5 (https=)
AU2024306568A9 (en) Albumin bound macromolecule tri-agonist activating glp-1/gip/glucagon receptors and methods therefor
AU2024246525A1 (en) Methods and uses for treating nausea and emesis